TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24471907

Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg once daily
Number of subjects: 1139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1139
Study: 22222224

Group type: EXPERIMENTAL
Intervention: Tramadol 25mg and Meloxicam 7.5mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Meloxicam 15mg
Number of subjects: 51

Group type: COMPARATOR
Intervention: Tramadol 50mg
Number of subjects: 51
Study: 18401549

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) 0.5 microg/kg/min i.v. for 20 min
Number of subjects: 6
Study: 16157010

Group type: EXPERIMENTAL
Intervention: COX‐2 inhibitor therapy (Rofecoxib) 25 mg/day for 10 days before surgery
Number of subjects: 50
Study: 12825134

Group type: EXPERIMENTAL
Intervention: UDCA at 600 mg/day plus bezafibrate at 400 mg/day
Number of subjects: 22

Group type: COMPARATOR
Intervention: UDCA at 600 mg/day (control group)
Number of subjects: 22
Study: 10971229

Group type: EXPERIMENTAL
Intervention: USA UDCA tablet
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Canadian UDCA tablet
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ursolvan capsules
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Actigall capsules
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Canadian UDCA tablet (dose proportionality)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: North American tablets
Number of subjects: 24
Study: 8795318

Group type: EXPERIMENTAL
Intervention: 10 ml of 0.25% bupivacaine plain solution
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20 ml of 0.25% bupivacaine plain solution
Number of subjects: 10
Study: 1458939

Group type: EXPERIMENTAL
Intervention: Dopamine infusion > 5 micrograms/kg/min for 4 hrs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dopamine infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (ICU patients not receiving dopamine)
Number of subjects: 0
Study: 2580183

Group type: EXPERIMENTAL
Intervention: Captopril (53 mg/day) + Calcium antagonist (verapamil 500 mg/day or nitrendipine 70 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Captopril (84 mg/day) + Diuretic
Number of subjects: 16
Study: 30892700

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoendocrine therapy (NCET)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (NCT)
Number of subjects: 249
Study: 30269241

Group type: EXPERIMENTAL
Intervention: Growth mindset (33 patients: 17 epidural, 16 PCA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fixed mindset (17 patients: 8 epidural, 9 PCA)
Number of subjects: 50
Study: 27380504

Group type: COMPARATOR
Intervention: Triple therapy (α‐blocker, anti‐inflammatory agent, muscle relaxant)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined extracorporeal shock-wave therapy (ESWT) and triple therapy
Number of subjects: 60
Study: 24767584

Group type: EXPERIMENTAL
Intervention: Strengthening, stretching, and functional training administered twice a week for 12 weeks to 26 patients.
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard medical care: pharmacological treatment for diabetes and foot care instructions administered to 29 patients.
Number of subjects: 55
Study: 22351381

Group type: EXPERIMENTAL
Intervention: Lamotrigine 100 mg/day
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 20538187

Group type: EXPERIMENTAL
Intervention: NGX‐4010, a high‐concentration capsaicin patch (capsaicin 8%)
Number of subjects: 106
Study: 18540853

Group type: EXPERIMENTAL
Intervention: High-quality randomized controlled trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systematic reviews and meta-analyses
Number of subjects: 0
Study: 16148470

Group type: EXPERIMENTAL
Intervention: SOFA scoring by ICU physicians
Number of subjects: 30
Study: 14580927

Group type: COMPARATOR
Intervention: Placebo (T0)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Single dose of inhaled salmeterol (50 microg) (T1)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Regular treatment with inhaled salmeterol (50 microg bid) for 1 week (T2)
Number of subjects: 53
Study: 10544919

Group type: EXPERIMENTAL
Intervention: Oral lefradafiban (the oral prodrug of fradafiban)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8703282

Group type: EXPERIMENTAL
Intervention: Skill training strategy (30 minutes session)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Insight training strategy (30 minutes session)
Number of subjects: 53
Study: 1898951

Group type: EXPERIMENTAL
Intervention: Immediate angioplasty
Number of subjects: 291

Group type: COMPARATOR
Intervention: Noninvasive treatment (rt-PA, aspirin, heparin without angioplasty)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Noninvasive treatment
Number of subjects: 291
Study: 6194145

Group type: EXPERIMENTAL
Intervention: Acyclovir (5 mg/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 29391372

Group type: EXPERIMENTAL
Intervention: Normal saline instillation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lung recruitment
Number of subjects: 0

Group type: COMPARATOR
Intervention: No normal saline instillation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No lung recruitment
Number of subjects: 0
Study: 26192160

Group type: EXPERIMENTAL
Intervention: Reappraisal
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 137
Study: 25545673

Group type: EXPERIMENTAL
Intervention: mesalamine
Number of subjects: 33
Study: 22781891

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) measurement
Number of subjects: 103
Study: 20459846

Group type: EXPERIMENTAL
Intervention: MoleMate system plus best practice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best practice alone
Number of subjects: 0
Study: 18669787

Group type: EXPERIMENTAL
Intervention: Heated humidification
Number of subjects: 16

Group type: COMPARATOR
Intervention: Heat and moisture exchanger
Number of subjects: 16
Study: 15933397

Group type: EXPERIMENTAL
Intervention: Home exercise program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative binomial regression models
Number of subjects: 0
Study: 14523700

Group type: EXPERIMENTAL
Intervention: Aerobic and strength training (A&ST) group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aerobic training only (ATO) group
Number of subjects: 40
Study: 10735983

Group type: EXPERIMENTAL
Intervention: Low-frequency TENS (4 Hz)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-frequency TENS (110 Hz)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study: 8695076

Group type: EXPERIMENTAL
Intervention: IV alfentanil (ALF) 10 mcg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Local anesthesia using plain lidocaine (XYL)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IV thiopental sodium (TPL) 1.5 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IV esmolol (ESM) 1 mg/kg
Number of subjects: 40
Study: 1514331

Group type: EXPERIMENTAL
Intervention: Aerosolized lidocaine 100 mg 2 min before tracheal intubation
Number of subjects: 193

Group type: COMPARATOR
Intervention: No spray (Control)
Number of subjects: 193
Study: 6476334

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg ketamine
Number of subjects: 20
Study: 30927644

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation with vitamin C (500 mg/d) and E (400 UI/d) for 15 days
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 29991707

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PgE1) therapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of PgE1 and endothelin‐1 blocker (bosentan)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 30
Study: 28545574

Group type: EXPERIMENTAL
Intervention: INCLUSIVE multi‐component intervention including a social and emotional learning curriculum, changes to school environment, and staff training in restorative practice.
Number of subjects: 6667

Group type: COMPARATOR
Intervention: Normal practice (control group).
Number of subjects: 6667

Group type: EXPERIMENTAL
Intervention: INCLUSIVE multi‐component intervention.
Number of subjects: 6667
Study: 25593496

Group type: EXPERIMENTAL
Intervention: BOACT group (240 mg bismuth subcitrate, 20 mg omeprazole, 1000 mg amoxicillin, 500 mg clarithromycin, 500 mg tinidazole)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: BOTMO group (240 mg bismuth subcitrate, 20 mg omeprazole, 500 mg tetracycline, 500 mg metronidazole, 200 mg ofloxacin)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: BOACT group
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: BOTMO group
Number of subjects: 208
Study: 22764197

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 µg daily for 12 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 21577221

Group type: COMPARATOR
Intervention: Arbaclofen placarbil (AP) 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Arbaclofen placarbil (AP) 30 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined Arbaclofen placarbil (AP) 20/30 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Arbaclofen placarbil (AP) 10 mg
Number of subjects: 0
Study: 17964767

Group type: EXPERIMENTAL
Intervention: PS/DAG oil
Number of subjects: 61

Group type: COMPARATOR
Intervention: TAG (control)
Number of subjects: 61

Group type: COMPARATOR
Intervention: DAG
Number of subjects: 61
Study: 16580899

Group type: EXPERIMENTAL
Intervention: Rofecoxib (50 mg daily)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg 4 times per day)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 12951544

Group type: EXPERIMENTAL
Intervention: STD treatment interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Community-based randomised controlled trials of STD interventions
Number of subjects: 0
Study: 11112003

Group type: EXPERIMENTAL
Intervention: Continuous retrograde warm blood reperfusion
Number of subjects: 42

Group type: COMPARATOR
Intervention: No reperfusion (control)
Number of subjects: 42
Study: 9132328

Group type: EXPERIMENTAL
Intervention: Patients with Jaccoud's syndrome (5 out of 23, 21.7%)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Patients meeting diagnostic criteria for SLE in the Jaccoud group (80%)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Patients without Jaccoud's syndrome
Number of subjects: 23
Study: 7522798

Group type: EXPERIMENTAL
Intervention: 127I-labeled peptides tested for their ability to displace 125I-T4 binding to thyroid hormone autoantibodies (THAA) in Graves' disease cases.
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 125I-labeled peptides tested for direct binding to antibodies.
Number of subjects: 2

Group type: COMPARATOR
Intervention: hTg obtained from a normal thyroid gland (NTg) and a case of Hürthle cell adenoma (CTg) tested for 125I-T4 binding displacement.
Number of subjects: 2
Study: 3028892

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of L‐3H‐NA
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 3H‐isoproterenol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: L‐3H‐noradrenaline infusion
Number of subjects: 16
Study: 27820726

Group type: EXPERIMENTAL
Intervention: HMB supplementation
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 26852075

Group type: EXPERIMENTAL
Intervention: Docetaxel 75mg/m2 + Abiraterone Acetate 1000mg + Prednisone 10mg
Number of subjects: 22
Study: 24369912

Group type: EXPERIMENTAL
Intervention: Low-protein/low-GI diet (LP/LGI)
Number of subjects: 938

Group type: EXPERIMENTAL
Intervention: Low-protein/high-GI diet (LP/HGI)
Number of subjects: 938

Group type: EXPERIMENTAL
Intervention: High-protein/low-GI diet (HP/LGI)
Number of subjects: 938

Group type: EXPERIMENTAL
Intervention: High-protein/high-GI diet (HP/HGI)
Number of subjects: 938

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 938

Group type: EXPERIMENTAL
Intervention: Low-calorie diet (initial phase)
Number of subjects: 938
Study: 22062334

Group type: EXPERIMENTAL
Intervention: Advance yield markings and pedestrian crosswalk prompt signs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard markings
Number of subjects: 0
Study: 19757354

Group type: EXPERIMENTAL
Intervention: Phospholipid-liposome eye spray (Tears Again)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Hyaluronate artificial tears (Vismed light)
Number of subjects: 216
Study: 18941964

Group type: EXPERIMENTAL
Intervention: Targeted clinical education on borderline personality disorder
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 99
Study: 16413604

Group type: EXPERIMENTAL
Intervention: Selegiline treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 12637483

Group type: EXPERIMENTAL
Intervention: Primary treatment
Number of subjects: 2306

Group type: EXPERIMENTAL
Intervention: Urinary function and bother
Number of subjects: 2306

Group type: EXPERIMENTAL
Intervention: Sexual function and bother
Number of subjects: 2306
Study: 10672286

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 46

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 46
Study: 8542001

Group type: EXPERIMENTAL
Intervention: AIDS education intervention
Number of subjects: 383

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 383
Study: 2064149

Group type: EXPERIMENTAL
Intervention: Systematic antiemetic prophylaxis (metilpednisolone 4 mg/Kg/dose/iv 2 doses; metodopamide 0.5 mg/Kg/dose/iv 4 doses; diphenydramine 1 mg/Kg/dose/iv 4 doses)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Systematic antiemetic prophylaxis
Number of subjects: 24
Study: 6796712

Group type: EXPERIMENTAL
Intervention: Vamin and Intralipid
Number of subjects: 122

Group type: COMPARATOR
Intervention: Travasol and hypertonic dextrose
Number of subjects: 122
Study: 31525358

Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty (BT)
Number of subjects: 68
Study: 29191262

Group type: EXPERIMENTAL
Intervention: Multiday training on evidence-based decision making
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 12
Study: 24740935

Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion (PP)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Non-pulsatile perfusion (NP)
Number of subjects: 46
Study: 23803895

Group type: COMPARATOR
Intervention: Lipid (pure lipid condition, L3)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Protein (pure protein condition, P3)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 2:1 lipid:protein combination (L2P1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 1:2 lipid:protein combination (L1P2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 17625308

Group type: EXPERIMENTAL
Intervention: Long-term infusion of gabexate (12 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-term infusion of gabexate (2.5 and 6.5 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-term administration of ulinastatin (10 minutes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term infusion of gabexate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-term administration of ulinastatin
Number of subjects: 0
Study: 15264730

Group type: EXPERIMENTAL
Intervention: Suntouch radiant warming
Number of subjects: 60

Group type: COMPARATOR
Intervention: Forced-air warming
Number of subjects: 60
Study: 11421841

Group type: EXPERIMENTAL
Intervention: Ropivacaine, 2 mg x ml(‐1) with continuous infusion of 6 ml x h(‐1) and PCEA bolus doses of 2 ml
Number of subjects: 51

Group type: COMPARATOR
Intervention: Bupivacaine, 2 mg x ml(‐1) with continuous infusion of 6 ml x h(‐1) and PCEA bolus doses of 2 ml
Number of subjects: 51
Study: 9284428

Group type: EXPERIMENTAL
Intervention: Diuretics and beta blockers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium channel blockers and ACE inhibitors
Number of subjects: 0
Study: 8491972

Group type: EXPERIMENTAL
Intervention: Squatting position during 2nd stage of labour
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Squatting position during delivery
Number of subjects: 200

Group type: COMPARATOR
Intervention: Supine position during delivery
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (supine position)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Squatting group
Number of subjects: 200
Study: 3126699

Group type: EXPERIMENTAL
Intervention: Magnesium hydroxide (25 ml daily)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Bulk-laxative (8.7 g daily)
Number of subjects: 64
Study: 11072596

Group type: EXPERIMENTAL
Intervention: Oral chicken type II collagen (CII) at 0.25 mg/day (n = 31)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (n = 29)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral chicken type II collagen (CII)
Number of subjects: 60
Study: 31241002

Group type: EXPERIMENTAL
Intervention: Prebiotic (10 g/day Inulin)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (10 g/day Maltodextrin)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups (Calorie restriction)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups (Weight loss)
Number of subjects: 62
Study: 31491682

Group type: EXPERIMENTAL
Intervention: Blue mussel diet (75g blue mussels, 5 days a week)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control diet (75g meat, 5 days a week)
Number of subjects: 23
Study: 28723835

Group type: EXPERIMENTAL
Intervention: Modified supine position (bed tilted 20° upright with a pillow between feet and the end of the bed)
Number of subjects: 300
Study: 26880594

Group type: EXPERIMENTAL
Intervention: TES+TAU
Number of subjects: 507

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: TES+TAU (subgroup not abstinent at study entry)
Number of subjects: 507
Study: 25006420

Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 405

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg or 40 mg
Number of subjects: 405
Study: 23144810

Group type: EXPERIMENTAL
Intervention: Vitamin D insufficiency (<30 ng/mL)
Number of subjects: 2588

Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency (<20 ng/mL)
Number of subjects: 2588

Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D concentrations categorized as <10, 10-20, 20-30, and ≥30 ng/mL
Number of subjects: 2588

Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D levels
Number of subjects: 2588
Study: 20413028

Group type: EXPERIMENTAL
Intervention: Rhythm-control strategy
Number of subjects: 1376

Group type: EXPERIMENTAL
Intervention: Sinus rhythm
Number of subjects: 1376
Study: 17419662

Group type: EXPERIMENTAL
Intervention: Intensive short-term music curriculum targeting reading comprehension and vocabulary skills
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control class (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive short-term music curriculum
Number of subjects: 0
Study: 15752880

Group type: EXPERIMENTAL
Intervention: Rectangular or conformal fields with a dose of 66 Gy
Number of subjects: 197
Study: 11907286

Group type: EXPERIMENTAL
Intervention: Implantable defibrillator
Number of subjects: 1232

Group type: COMPARATOR
Intervention: Conventional medical therapy
Number of subjects: 1232

Group type: COMPARATOR
Intervention: Implantable defibrillator vs Conventional medical therapy
Number of subjects: 1232
Study: 10436100

Group type: EXPERIMENTAL
Intervention: Plasma homocyst(e)ine level >/= 7.3 micromol/L
Number of subjects: 495

Group type: COMPARATOR
Intervention: Control group (plasma homocyst(e)ine level < 7.3 micromol/L)
Number of subjects: 495
Study: 7776516

Group type: EXPERIMENTAL
Intervention: 0.7 MAC nitrous oxide
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.7 MAC sevoflurane
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.7 MAC nitrous oxide after induction of anesthesia
Number of subjects: 10
Study: 2130078

Group type: EXPERIMENTAL
Intervention: Hydroxyzine and Diazepam
Number of subjects: 14

Group type: COMPARATOR
Intervention: Chloral hydrate and Promethazine
Number of subjects: 14
Study: 288172

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 273

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 273

Group type: COMPARATOR
Intervention: General health survey with mass miniature chest X‐ray
Number of subjects: 273
Study: 29397659

Group type: EXPERIMENTAL
Intervention: S‐1 plus docetaxel (DS)
Number of subjects: 153

Group type: COMPARATOR
Intervention: S‐1 plus cisplatin (SP)
Number of subjects: 153
Study: 27632195

Group type: EXPERIMENTAL
Intervention: Compression socks worn during the recovery period
Number of subjects: 12

Group type: COMPARATOR
Intervention: No compression socks worn during the recovery period (control)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Compression socks worn during the recovery period (for participants with strong beliefs)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Compression socks worn during the recovery period (for participants with neutral or negative perceptions)
Number of subjects: 12
Study: 25958473

Group type: EXPERIMENTAL
Intervention: CABG surgery and intramyocardial implantation of BMMNC
Number of subjects: 30

Group type: COMPARATOR
Intervention: CABG surgery only
Number of subjects: 30
Study: 24223740

Group type: EXPERIMENTAL
Intervention: Oral paracetamol
Number of subjects: 160

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 160
Study: 21336804

Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 7665

Group type: EXPERIMENTAL
Intervention: ACEIs or ARBs
Number of subjects: 7665

Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 7665

Group type: EXPERIMENTAL
Intervention: Lipid-lowering drugs
Number of subjects: 7665

Group type: EXPERIMENTAL
Intervention: Anti-platelet drugs
Number of subjects: 7665

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 7665

Group type: EXPERIMENTAL
Intervention: Coronary artery by-pass grafting (CABG)
Number of subjects: 7665